T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and/or bispecific antibody (BsAb) has been established and become a promising treatment strategy for relapsed/refractory B-cell ...
NEW ORLEANS — A novel, off-the-shelf antibody, talquetamab, has shown high response rates among patients with heavily pretreated multiple myeloma in both phase 1 and now phase 2 studies, which have ...
A version of this article was originally published on CancerNetwork. This version has been lightly edited. The FDA has granted accelerated approval to talquetamab-tgvs (Talvey) for patients with ...
A CAR-T cell product can contain both CAR-T cells and CAR-negative bystander T cells (left). After treatment with CAR-T cell therapy, CAR-T cells kill tumor cells and release a panel of cytokines. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results